‘Uncertainty’ among insurers over Trump’s ACA plans

Insurance companies are worried plans to repeal and replace the Affordable Care Act (ACA) may create the very “death spiral” opponents of the law have claimed is already happening.

President-elect Donald Trump has said he’d like to keep two parts of the ACA: the ban on insurers denying coverage based on preexisting conditions and keeping kids on their parents’ plans until they reach the age of 26. According to The Hill, insurers want to warn the Trump administration that without requirements for buy health insurance, only sick people will purchase coverage, sending premiums skyrocketing and causing the market to collapse—a “death spiral.”

“There’s a huge amount of uncertainty that I think freaks them out a little bit,” one insurance lobbyist said.

A cautionary tale can be found in New York, where before the ACA existed, a pre-existing condition ban with no individual mandate was put into place. The plan failed.

“It was a market in a death spiral, and by that I mean the premiums were exorbitantly expensive,” Sabrina Corlette, a health policy professor at Georgetown University. “Very few people were able to enroll.”

For more on how even a delayed repeal of the ACA worries insurers, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.